Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya.

Схожие документы

• Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice.
  по: Hanke, T, и др.
  Опубликовано: (2005)
• Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA)
  по: Schmidt, C, и др.
  Опубликовано: (2008)
• Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.
  по: Peters, B, и др.
  Опубликовано: (2007)
• Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
  по: Jeffrey R Currier, и др.
  Опубликовано: (2010-11-01)
• Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain
  по: L. F. Stovba, и др.
  Опубликовано: (2023-04-01)